Nanolattix Debuts ANEN Technology During a Top Rated Oral Presentation at EANM'26

The European Association of Nuclear Medicine's 2026 Congress (EANM'26) was held in Vienna, Austria, from October 17 to 21. Dr. Zhican Qu, founder, chairman and chief scientific officer of Shanxi-based Nanolattix, introduced the company's proprietary antibody analysis and modification technology, ANEN, for the first time in her presentation of a HER2/TF dual-target study selected as a Top Rated Oral Presentation (TROP). Using the radionuclide drug conjugate (RDC) candidate RB02 as an example, she showed how the team used antibody engineering to improve the drug's biodistribution.

To address tumor heterogeneity, resistance to targeted therapies, and the limited integration of diagnostic information into therapeutic drug development, Nanolattix has proposed an RDC+ADC 'See & Treat' development framework. Diagnostic RDC imaging maps the distribution of a targeting molecule in lesions and throughout the body, providing information for the development of therapeutic RDCs and antibody-drug conjugates (ADCs). The two therapeutic modalities are also developed in a coordinated manner, drawing on the distinct mechanisms of radiation delivered by radionuclides and cytotoxic ADC payloads. RB02 and the ADC candidate B836, both discussed in the presentation, are representative programs within this framework.
RB02 and B836 use the same bispecific antibody targeting HER2 and tissue factor (TF). RB02 carries a radionuclide, while B836 carries a cytotoxic payload. The dual-target design aims to cover tumor cell populations with differing HER2 and TF expression. Once the targets had been selected, the team also had to adapt the antibody to the distinct development requirements of the two payload types.
Small molecules and peptides, which generally enter tissues and clear from the body relatively quickly, are widely used as carriers for radiopharmaceuticals. Antibodies offer high target specificity, can recognize complex cell-surface structures, and support dual-target designs such as HER2/TF. Their longer retention in lesions may also allow therapeutic radionuclides to act over an extended period. At the same time, antibodies circulate in the blood for longer and penetrate deep into solid tumors more slowly. When paired with a radionuclide, radiation exposure in normal tissues must also be considered. These properties make antibody engineering an important part of antibody-based RDC development.

ANEN is a key module of Nanolattix's BioLattix technology platform, linking target research with the design and construction of antibody-based targeting ligands. During RB02 development, the team used in vivo imaging and evaluation results to refine the antibody with ANEN, then reassessed its biodistribution. In the animal studies presented, the ANEN-optimized RB02 showed increased uptake in tumor lesions, markedly lower accumulation in non-target organs, and favorable antitumor activity.
Antibody-based radiopharmaceuticals are not new: earlier products were approved for hematologic malignancies, and programs targeting solid tumors have since reached late-stage clinical development. Companies in the field have also built proprietary antibody-engineering platforms. In its TLX592 program, Telix applies RADmAb engineered-antibody technology to accelerate blood clearance while retaining target recognition. Abdera uses its ROVEr platform to tune the pharmacokinetics of antibody carriers to the delivery requirements of selected radionuclides. These efforts show that competition in antibody-based radiopharmaceuticals now extends to carrier engineering. With ANEN, Nanolattix has introduced its own technology for this critical stage of development.
Within the HER2/TF program, RB02 labeled with zirconium-89 is being studied for imaging, while versions labeled with lutetium-177 and actinium-225 are being evaluated for therapy. An investigator-initiated trial (IIT) of the imaging version is underway. B836, the ADC developed from the same bispecific antibody, has completed Good Laboratory Practice (GLP) pharmacokinetic and safety evaluations and is preparing to enter clinical studies.

From AACR and ASCO earlier this year to EANM'26, Nanolattix has presented its single- and dual-target RDC and ADC programs. As Dr. Qu noted at the close of her presentation, RB02 and B836 are just one pair of examples from the company's theranostic pipeline. Additional dual-target programs, including RB835, RB837 and RB839, are advancing. The introduction of ANEN highlights the in-house antibody-engineering capabilities supporting Nanolattix's RDC and ADC pipelines. The company has developed an approach linking in vivo evaluation to antibody refinement that can be extended to the design and optimization of future dual- and even multi-target candidates.